Alembic Pharmaceuticals Ltd's Oncology facility successfully completes USFDA inspection

Alembic Pharmaceuticals Limited has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Oncology (Injectable and Oral Solid) Formulation Facility (F-2) located at Panelav. The inspection was successfully completed without any Form 483 observation. The inspection was conducted from 7th October, 2024 to 8th October, 2024.

Shares of Alembic Pharmaceuticals Limited was last trading in BSE at Rs. 1230.60 as compared to the previous close of Rs. 1246.45. The total number of shares traded during the day was 21938 in over 1710 trades.

The stock hit an intraday high of Rs. 1296.15 and intraday low of 1226.00. The net turnover during the day was Rs. 27830105.00.

Source : Equity Bulls

Keywords

AlembicPharmaceuticals INE901L01018 USFDA Inspection Oncology FormulationFacility Panelav ZeroObservation